Azathioprine in Behçet's syndrome. Effects on long‐term prognosis

Hamuryudan, Vedat; Özyazgan, Yılmaz; Hizli, Nail; Mat, Cem; Yurdakul, Sebahattin; Tüzün, Yalçın; Şlenocak, Mustafa; Yazıcı, Hasan

doi:10.1002/art.1780400425

Cited by 249 publications

(76 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only 1 (11%) of 9 patients with posterior eye involvement had loss of useful vision in at least 1 eye at the end of the followup, whereas almost all patients had improvement of visual acuity once treatment was started. The improved prognosis may be attributed to the early aggressive treatment with immunosuppressive agents and oral corticosteroids (7,53) and possibly to the long-term use of cyclosporin in most patients (50,52). In agreement with Kural-Seyahi et al (7), we demonstrated that the frequency and severity of eye involvement decreased over time.…”

Section: Seventeen-year Study Of Behçet's Disease In Italysupporting

confidence: 90%

Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A seventeen‐year population‐based study

Salvarani¹,

Pipitone²,

Catanoso³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To investigate the epidemiology and clinical course of Behçet's disease (BD) over a 17-year period in a defined area of northern Italy. Methods. All patients with incident BD diagnosed over a 17-year period (from January 1, 1988 to December 31, 2004) living in the Reggio Emilia area were identified through the following sources: physicians at Reggio Emilia Hospital, medical practitioners, and community-based specialists. We identified all patients registered in a centralized index and in the Reggio Emilia district database for rare diseases. Patients were followed up from the time of diagnosis until either their death or April 1, 2005. Results. Eighteen patients (9 men and 9 women) had complete BD. Mean ؎ SD age at diagnosis was 33 ؎ 7 years. The incidence rate of BD was 0.24 per 100,000. The prevalence of BD on January 1, 2005 was 3.8 per 100,000. No patients died during the followup period. Although all patients developed oral ulceration during the disease course, 22.2% had no oral lesions at disease onset. Eye disease occurred in 55.6%. Ocular disease was more common in men and appeared at disease onset or within the first few years of disease onset (median 3 years). Only 1 patient had loss of useful vision in at least 1 eye at the end of followup. In all affected patients, visual acuity improved once treatment was started. Conclusion. This population-based study is the first to report the prevalence and incidence of BD in Italy. In Italian patients, BD is nonfatal and the prognosis of eye disease is good.

show abstract

Section: Seventeen-year Study Of Behçet's Disease In Italysupporting

confidence: 90%

Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A seventeen‐year population‐based study

Salvarani¹,

Pipitone²,

Catanoso³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…25,26 Mycophenolate mofetil (MMF; 2-3 gm/day orally) is an inhibitor of T-and B-lymphocytes. Dapsone (2-3 mg/kg/day), through its anti-inflammatory and bactericidal properties, has a role in cutaneous disease.…”

Section: Managementmentioning

confidence: 99%

Behcet’s disease

2017

View full text Add to dashboard Cite

Behçet's disease (BD) is a chronic relapsing and remitting vasculitis of unknown aetiology. It has the capacity to affect almost all organ systems because of its potential to involve both arteries and veins of all sizes, resulting in significant organ-threatening morbidity and mortality. Traditionally known as the 'silk road' disease, it has a worldwide occurrence. The aetiopathological mechanisms of disease development in BD remain poorly understood, but genome wide studies show human leukocyte antigen and non-human leukocyte antigen associations. Environmental influences and genetic factors may have a role in the aetiopathogenetic mechanisms that lead to development of the disease, indicating the autoimmune and auto-inflammatory nature of BD. The evidence base for treatment is limited but new knowledge is emerging and current treatment options range from symptomatic treatment, through to non-biological and biological immunosuppressive drugs, to cover the spectrum of clinical manifestations.

show abstract

“…El tratamiento de la EB se hace de acuerdo con los síntomas y territorios comprometidos, principalmente se han utilizado corticoesteroides tópicos y sistémicos, inmunosupresores y fárma-cos biológicos anti factor de necrosis tumoral (FNT) alfa [12][13][14] . Para el compromiso de mucosas, especialmente en genitales con lesiones que, si son de mayor tamaño, pueden dejar cicatrices 15 , se recomienda iniciar terapia con agentes como lidocaína combinada con corticoesteroides tópicos.…”

Section: Discussionunclassified